<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428373</url>
  </required_header>
  <id_info>
    <org_study_id>10014356</org_study_id>
    <nct_id>NCT03428373</nct_id>
  </id_info>
  <brief_title>ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.</brief_title>
  <acronym>RithMM</acronym>
  <official_title>Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intended pilot study is designed as a multicenter randomized controlled clinical trial,
      comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly
      diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide
      Dexamethasone (Len-Dex) combination therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a pragmatic multicentre open label pilot randomized controlled
      trial in Canada (London, Hamilton, Ottawa, Halifax, Winnipeg ) to assess the feasibility of a
      full RCT to compare the efficacy and safety of Rivaroxaban or ASA in preventing venous or
      arterial thromboembolic events in patients with myeloma on Len-Dex based therapy. For the
      data collection the research team will use REDCap which is a Research Electronic Data Capture
      web-based tool for creating and managing online database applications and surveys. System
      will allow performing the randomization as well. Patients will be randomized to ASA 81 mg
      daily or Rivaroxaban 10 mg daily. Patients will enter the study at the time of commencement
      of anticoagulants (Rvaroxaban or ASA) and be followed for 6 months, or until 4 weeks after
      stopping Len-Dex, or they withdraw from the study, or they leave the province, or die,
      whichever comes first. Patients will be randomly assigned, in a 1: 1 ratio, to receive either
      Rivaroxaban 10 mg daily for 6 months or ASA 81 mg daily for 6 months. A web-based
      randomization system will ensure allocation concealment. Randomization will be stratified by
      site and by line of therapy (first line or other) in blocks of 4. Using a vanguard design,
      the research team intends to rollover the participants of our feasibility study into a full
      randomized control trial comparing the efficacy and safety of Rivaroxaban or ASA in
      preventing venous or arterial thromboembolic events (ATE) in myeloma patients receiving
      Len-Dex therapy. For the full RCT, the investigators plan to externally validate the IMWG
      criteria model for thromboembolic risk. The investigators will also evaluate the impact of
      adding myeloma bio-markers to the IMWG criteria to assess their association with TE risk and
      potentially improve the utility and generalizability of the IMWG criteria. The bio-markers
      are: D-dimer, LDH, B2 microglobulin and C-reactive protein (CRP). All of the IMWG criteria
      risk factors and the bio-markers will be collected for the participants of the feasibility
      study for potential future enrollment into the full RCT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis assessment of patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin</measure>
    <time_frame>6 months</time_frame>
    <description>Participants that develop symptoms of venous or arterial thromboembolism will be assessed as per standard of care such as Doppler ultrasound for deep venous thrombosis ad CTPA or V/Q lung scan for Pulmonary embolism; and appropriate cardiac interventions for coronary events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency and severity of adverse events and serious AEs based on hospital admission and patientself reporting events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma Progression</condition>
  <condition>Multiple Myeloma Stage II</condition>
  <condition>Multiple Myeloma Stage I</condition>
  <condition>Multiple Myeloma With Failed Remission</condition>
  <condition>Multiple Myeloma Stage III</condition>
  <arm_group>
    <arm_group_label>Len-Dex+Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Len-Dex+ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients MM will receive Len-Dex combination and ASA 81 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 10mg daily</description>
    <arm_group_label>Len-Dex+Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>ASA 81mg</description>
    <arm_group_label>Len-Dex+ASA</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with NDMM or RRMM

          -  Must be receiving Len-Dex based treatment

        Exclusion Criteria:

          -  Creatinine clearance (CrCl) is less than 15mL/min;

          -  Platelet count is less than 50,000;

          -  Major bleeding event within the previous 3 months prior to the Len-Dex therapy;

          -  previous recent anticoagulation or on antiplatelet therapy

          -  previous lenalidomide maintenance therapy

          -  known allergies to any of the study drugs

          -  history of gastric or duodenal ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martha Louzada, MD MSc (Epid)</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>52391</phone_ext>
    <email>Martha.Louzada@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Kelly, M.Sc. MPH/Gero</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>54511</phone_ext>
    <email>Kate.Kelly@lhsc.on.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Kamat AV Rivaroxaban Is an Effective and Well Tolerated Anti Thrombotic Agent in Patients on Lenalidomide Therapy and in Multiple Myeloma Blood 2014 124:5095;</citation>
  </reference>
  <results_reference>
    <citation>Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010 Jul 16;10:67. doi: 10.1186/1471-2288-10-67. Review.</citation>
    <PMID>20637084</PMID>
  </results_reference>
  <results_reference>
    <citation>Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004 May;10(2):307-12.</citation>
    <PMID>15189396</PMID>
  </results_reference>
  <results_reference>
    <citation>Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blad√© J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.</citation>
    <PMID>18094721</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Ani F, Bermejo JM, Mateos MV, Louzada M. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res. 2016 May;141:84-90. doi: 10.1016/j.thromres.2016.03.006. Epub 2016 Mar 5. Review.</citation>
    <PMID>26986753</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, Ramirez L, Julian J. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012 May;10(5):807-14. doi: 10.1111/j.1538-7836.2012.04693.x.</citation>
    <PMID>22409262</PMID>
  </results_reference>
  <results_reference>
    <citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.</citation>
    <PMID>15842354</PMID>
  </results_reference>
  <results_reference>
    <citation>Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaleteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Fermand JP, Moreau P. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost. 2013 Oct;110(4):844-51. doi: 10.1160/TH13-02-0140. Epub 2013 Aug 1.</citation>
    <PMID>23903204</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Martha Louzada</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

